ClinicalTrials.Veeva

Menu

Arterial Stiffening as a Predictor for Diastolic Cardiac Dysfunction and HFpEF (ARTSPREDICTION)

U

University Medical Center Goettingen

Status

Enrolling

Conditions

Cardiovascular Morbidity
Heart Failure With Preserved Ejection Fraction

Study type

Observational

Funder types

Other

Identifiers

NCT06208007
9/12/23

Details and patient eligibility

About

Patients at risk for developing heart failure with preserved ejection fraction (HFpEF) will undergo a structured clinical assessment, transthoracic echocardiography and pulse-wave analysis to investigate the association of arterial stiffening and the development of cardiac diastolic dysfuntion and HFpEF.

Enrollment

150 estimated patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

One or more of the following criteria:

  • Age > 60 years
  • Arterial hypertension (RR systolic ≥ 140 mmHg or diastolic ≥ 90 mmHg or ≥ 2 antihypertensive drugs)
  • Diabetes mellitus Type I or II
  • Atrial fibrillation
  • Chronic kidney disease (GFR < 60 ml/min/1,73 m2 or urine albumin ≥ 30mg/24h or ACR ≥ 30 mg/g)
  • BMI ≥ 30 kg/m2
  • NYHA ≥ II
  • E/e' > 8

Exclusion criteria

  • Left ventricular ejection fraction < 50 %
  • Significant valve disease (Grade III or higher)
  • History of interventional or surgical valve repair
  • Regional wall motion abnormalities
  • Respiratory diseases as a known cause for dyspnea
  • Atrial flutter or fibrillation during examination
  • Hypertrophic/restrictive/arrhythmogenic/dilatative cardiomyopathies including cardiac amyloidosis or sarcoidosis and toxic cardiomyopathy
  • History of heart transplantation

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems